Abnormal activation of Hh signaling, through loss of Hh receptor, Patched1 (Ptch1), or activation of Smo induces medulloblastomas in mice[@R17]--[@R22]. To induce medulloblastoma we expressed constitutively active Smo (SmoM2) in GNPs using a human *Glial Fibrillary Acidic Protein* promoter-driven Cre (*hGFAP::Cre*)[@R21]. By postnatal day (P) 10, *hGFAP::Cre*; *SmoM2^fl/+^* mice developed medulloblastoma (*n* = 7) ([Fig. 1a](#F1){ref-type="fig"}). In these tumors, SmoM2 fused with yellow fluorescent protein localized to primary cilia ([Fig. 1b](#F1){ref-type="fig"}). To investigate whether SmoM2-driven medulloblastoma formation requires primary cilia, we removed primary cilia from GNPs expressing SmoM2, using a conditional allele of *Kif3a* that encodes a subunit of the kinesin-II motor essential for ciliogenesis[@R23]--[@R25]. The removal of *Kif3a* and the consequent loss of cilia completely blocked tumorigenesis (*n* = 7). The cerebellum of the *hGFAP::Cre*; *SmoM2^fl/+^*; *Kif3a^fl/fl^* mice resembled that of *hGFAP::Cre*; *Kif3a^fl/fl^* mice ([Fig. 1a](#F1){ref-type="fig"}), which fail to expand GNPs[@R8],[@R13]. Loss of *Ift88*, another gene essential for ciliogenesis[@R26],[@R27] in *hGFAP::Cre*; *SmoM2^fl/+^*; *Ift88^fl/fl^* mice also blocked tumorigenesis driven by SmoM2 ([Supplementary Fig. 1a](#SD2){ref-type="supplementary-material"}).

At E16, when the number of GNPs is not affected by removing cilia[@R8], EGL was already expanded with many proliferating cells in *hGFAP::Cre*; *SmoM2^fl/+^* mice but not in *hGFAP::Cre*; *SmoM2^fl/+^*; *Kif3a^fl/fl^* mice ([Fig. 1c,d](#F1){ref-type="fig"}), suggesting that SmoM2 requires Kif3a to initiate the aberrant GNP expansion and medulloblastoma. Similar requirement of cilia for SmoM2-driven expansion of GNPs was observed in the hippocampal dentate gyrus[@R4].

Activated Smo converts Gli2 into a transcriptional activator and inhibits the formation of Gli3 repressors that form constitutively in the absence of Hh signaling[@R28]. We hypothesized that constitutively active Gli2 could induce medulloblastomas in the absence of primary cilia. To test this hypothesis we used *CLEG2* mice that upon Cre-mediated recombination express a constitutively active Gli2 that lacks the N-terminal repressor domain (Gli2ΔN)[@R29],[@R30]. Unexpectedly, none of *hGFAP::Cre*; *CLEG2^fl/+^* mice (*n* = 14) developed medulloblastoma ([Fig. 2](#F2){ref-type="fig"}) albeit two had a different type of tumors (see below). Surprisingly, unlike *hGFAP::Cre*; *CLEG2^fl/+^* mice, removal of primary cilia in *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice induced medulloblastomas between P11 and P30 (*n* = 11) ([Fig. 2](#F2){ref-type="fig"}). Tumors in *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice contained two types of cells frequently segregated into distinct zones: cells with darkly stained nuclei and lightly stained cytoplasm (type 1), and cells with large nuclei and highly eosinophilic cytoplasm (type 2) ([Fig. 2b,c](#F2){ref-type="fig"}). Both cell types were actively proliferating ([Fig. 2f](#F2){ref-type="fig"}) and expressed *Gli1*, suggesting active Hh signaling ([Supplementary Fig. 2](#SD2){ref-type="supplementary-material"}). The type 1 tumor cells were indistinguishable from those in SmoM2-driven medulloblastoma[@R18],[@R19],[@R21] and reminiscent of classic medulloblastoma cells: small round cells with high nuclear-to-cytoplasmic ratio. Type 1 cells exhibited immunohistological characteristics of medulloblastoma similar to those in SmoM2 tumor: neuronal (Tuj1), glial (GFAP and Olig2), GNP (Pax6), and granule neuron (Zic1) markers ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}). *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* and *hGFAP::Cre*; *SmoM2^fl/+^* mice also had very similar gene expression profiles ([Fig. 2h](#F2){ref-type="fig"}): up-regulation of Hh-responsive genes characteristic of medulloblastoma cells (*Gli1, Gli2, Ptch1, Ptch2, Mycn, Ccnd2, Atoh1*, and *Bmi1*). The expression of *Gli3* and *Wif1* were different between the two tumors likely due to the presence of type 2 tumor cells in *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice; type 2 tumor cells down-regulated *Gli3* and up-regulated *Wif1* ([Fig. 2h](#F2){ref-type="fig"} and see below). Type 2 tumors lacked immunohistological characteristics of medulloblastoma markers ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}), but expressed Sox2 (data not shown), suggesting that these are not medulloblastomas. Type 2 tumors were also found outside of cerebellum, suggesting that these cells have a different origin ([Supplementary Fig. 4a](#SD2){ref-type="supplementary-material"}). Both tumor types lacked primary cilia ([Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}). Similar to loss of *Kif3*a, loss of *Ift88* promoted tumor formation containing both type 1 and 2 tumor cells in *hGFAP::Cre*; *CLEG2^fl/+^*; *Ift88^fl/fl^* mice ([Supplementary Fig. 1b](#SD2){ref-type="supplementary-material"}).

*hGFAP::Cre*; *CLEG2^fl/+^* mice developed only type 2 tumors later in life that were found throughout central nervous system ([Supplementary Fig. 4b](#SD2){ref-type="supplementary-material"}) and lived significantly longer than *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice (*P* \< 0.0001, *n* = 19) ([Fig. 2g](#F2){ref-type="fig"}). These tumors expressed high levels of Hh-responsive genes (*Gli1, Gli2, Ptch1, Ptch2, Mycn*, and *Ccnd2*) and Wnt-responsive genes (*Axin2* and *Wif1*), but not genes associated with GNPs and medulloblastoma (*Atoh1*[@R20] and *Bmi1*[@R31]) ([Fig. 2h](#F2){ref-type="fig"}). Type 2 tumors in *hGFAP::Cre*; *CLEG2^fl/+^* mice had primary cilia, excluding the possibility that they may have originated from cells that spontaneously lost primary cilia ([Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}). Thus, loss of cilia is required for medulloblastoma development driven by Gli2ΔN, but not for type 2 tumors; yet, loss of cilia accelerated the development of the type 2 tumor ([Fig. 2a--c,g](#F2){ref-type="fig"}).

The above results suggest that loss of primary cilia is required for Gli2ΔN-driven medulloblastoma development, which is in striking contrast to their requirement for SmoM2-driven tumorigenesis. One possible explanation for these opposite roles is that primary cilia are required not only for Smo function but also for Gli3 repressor formation[@R2],[@R6],[@R7],[@R9]. Consistently, Gli3 repressor was dramatically reduced in *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice compared with wild-type or *hGFAP::Cre*; *CLEG2^fl/+^* mice ([Fig. 2d](#F2){ref-type="fig"}). *Gli3* expression was also significantly decreased in type 2 tumors in *hGFAP::Cre*; *CLEG2^fl/+^* mice ([Fig. 2h](#F2){ref-type="fig"}), suggesting Gli3 could also have an inhibitory role in these tumors. Since *Gli3* null mutants are embryonic lethal, we removed one copy of *Gli3* in mice expressing Gli2ΔN (*hGFAP::Cre*; *CLEG2^fl/+^*; *Gli3^Xt/+^*) to test if Gli3 has an inhibitory effect on Gli2ΔN-driven tumorigenesis. *hGFAP::Cre*; *CLEG2^fl/+^*; *Gli3^Xt/+^* mice developed type 2 tumors and died earlier in life than *hGFAP::Cre*; *CLEG2^fl/+^* mice (*P* \< 0.02, *n* = 18) ([Fig. 2g](#F2){ref-type="fig"} and [Supplementary Fig. 6](#SD2){ref-type="supplementary-material"}). Thus, loss of one copy of *Gli3* induces earlier development of the type 2 tumors in the presence of primary cilia, supporting our inference that Gli3 repressors may mediate the inhibitory function of primary cilia in tumorigenesis driven by Gli2ΔN. Interestingly, *hGFAP::Cre*; *CLEG2^fl/+^*; *Gli3^Xt/+^* mice did not develop medulloblastoma, possibly due to the presence of one copy of *Gli3*. Additionally, loss of primary cilia could interfere with other signaling pathways that contribute to medulloblastoma development.

While *SMOM2* mutations have been observed in one case of human medulloblastoma[@R32], activating mutations in GLI transcription factors have not been described in medulloblastoma. Thus, our mouse models reveal important roles of primary cilia in tumorigenesis, but might not reflect on the behavior of this organelle in human cases. To determine if our observations in mice are relevant to human tumors, we analyzed 38 human medulloblastomas for the presence of cilia. Presence of primary cilia was significantly associated with desmoplastic medulloblastoma (*P* \< 0.02); whereas the absence of cilia was significantly associated with anaplastic medulloblastoma (*P* \< 0.05) ([Fig. 3a](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Twenty-four of these samples were analyzed previously for gene expression profiling[@R33]. Remarkably, in these 24 samples, cilia were identified almost exclusively in tumors that have activation in either HH or WNT signaling (*P* \< 0.0001, [Table 1](#T1){ref-type="table"}). Two of the four tumors with active HH signaling had inactivating mutations in *PTCH1*[@R33], which functions upstream of SMO and primary cilia[@R5].

Our results suggest that primary cilia can be permissive or inhibitory for tumor formation depending on the underlying oncogenic events ([Fig. 3b](#F3){ref-type="fig"}). Interestingly, we found that subsets of human medulloblastomas have primary cilia, while others do not. Our mouse models predict both presence and absence of primary cilia in HH signaling-driven medulloblastomas, but all the observed medulloblastomas with high HH signaling activity had primary cilia. This suggests that medulloblastomas with high HH signaling in humans are largely due to mutations upstream of the primary cilia such as mutations in *PTCH1*. Oncogenic mutations in downstream molecules including GLI transcription factors, which would require loss of repressor activity mediated by the cilia, are rare[@R11]. A recent study identified rare amplifications of *GLI1* and *GLI2* genes in medulloblastomas[@R34], but it is not known if these tumors are ciliated. Analyses of more medulloblastomas for both oncogenic mutations and presence/absence of primary cilia will be necessary to delineate the role of cilia in human medulloblastoma. Interestingly, all the observed human medulloblastomas with high WNT signaling had primary cilia. All these tumors had mutations in *CTNNB1*. It is possible that primary cilia are also involved in WNT signaling pathway[@R35]--[@R37] or that oncogenic WNT activation requires concomitant signaling through primary cilia to induce medulloblastoma.

Our observations suggest that the presence of primary cilia be important for tumor diagnosis and treatment. HH signaling mutations found in medulloblastomas, loss of PTCH1 and SMO activation, act upstream of primary cilia[@R2],[@R4]--[@R9]. Ciliated medulloblastomas showing HH signature would be susceptible to treatments that target primary cilia. The loss of cilia in subgroups of medulloblastomas suggests that tumor repressor functions mediated through primary cilia could serve as therapeutic targets to inhibit tumor growth. GLI3 is a strong candidate, but primary cilia could have multiple repressor activities. Understanding the role of primary cilia in normal and oncogenic signaling could lead to better understanding of tumor development and treatment not only in medulloblastomas, but also in other tumors (see Wong et al, this issue).

METHODS {#S1}
=======

Mice {#S2}
----

All animal procedures were approved by the UCSF Institutional Animal Care and Use Committee. Genetically modified mice used in the study were described previously: *hGFAP::Cre*[@R39], *Kif3a^fl/fl^* [@R24], *SmoM2-YFP^fl/fl^* [@R19],*Ift88*[@R26], *CLEG2*[@R29].

Tissue preparation and staining {#S3}
-------------------------------

Mice were injected with BrdU (50 mg kg^−1^) and perfused one hour later with 4% paraformaldehyde. The brains were postfixed overnight at 4°C. For frozen sections, brains were cryoprotected in 30% sucrose, embedded in OCT, and cut at 10 µm. For polyethylene glycol (PEG) sections, brains were dehydrated in an ethanol series, embedded in a 2:1 mixture of PEG 1000 and PEG 1500, and cut at 8 µm. For immunostaining, sections were incubated with primary antibodies overnight at 4°C followed by incubation with secondary antibodies at room temperature for two hours. Images were taken with an Olympus AX70 microscope, Leica SP2 or SP5 confocal microscopes, and processed using Adobe Photoshop.

Antibodies and reagents {#S4}
-----------------------

The following primary antibodies were used: rat anti-BrdU (1:1000 Abcam), mouse anti-acetylated tubulin (1:1000 Sigma), anti-GFAP (1:1000 Chemicon), anti-Tuj1 (1:500 Covance), rabbit anti-γ-tubulin (1:1000 Sigma), anti-Zic (recognizes Zic1 and other Zic proteins, gift from Dr. R. Segal, Boston, 1:3000), anti-Olig2 (DF308, gift from Dr. C. Stiles, Boston, 1:20,000) anti-pericentrin (1:1000 Abcam), Goat anti-Pax6 (1:50 Santa Cruz) and chicken anti-GFP (1:500 Aves Labs). SmoM2-YFP was visualized by Anti-GFP antibody. Alexa Fluor-conjugated secondary antibodies (1:400 Molecular Probes) were used and DAPI (200 ng ml^−1^) was used for counter staining. Standard hematoxylin and eosin staining was used.

*Gli1 in situ* hybridization {#S5}
----------------------------

Standard *in situ* protocol and antisense riboprobe from *Gli1* cDNA (gift from A. Ruiz i Altaba) were used.

Western blot {#S6}
------------

Whole cerebella of P23 mice were lysed in RIPA buffer. Pellets were removed after centrifugation. Lysates were resolved in 7% SDS-PAGE gel. Rabbit anti-Gli3 antibody (1:500 Santa Cruz biotechnology, H280) was used for immunoblotting. This Gli3 antibody detects specific Gli3 bands that are absent in Gli3 mutants and non-specific bands[@R38].

qRT-PCR {#S7}
-------

Total RNA was isolated from each tumor of an individual mouse (*n* = 3 per group) using RNeasy Mini Kit (Qiagen) and was reverse transcribed by Superscript III reverse transcriptase (Invitrogen). Quantitative PCR was performed on an Applied Biosystems 7900 quantitative PCR instrument using SYBR green. Transcript levels were normalized to the expression levels of *Gapdh* and measured relative to those in wild-type cerebellum. Primer sequences are listed in [supplementary table 1](#SD1){ref-type="supplementary-material"}.

Human medulloblastoma samples {#S8}
-----------------------------

Sections were prepared from formalin-fixed paraffin-embedded medulloblastomas archived in the Neurological Surgery Tissue Bank at UCSF or Neuropathology Laboratory at St. Jude Children's Research Hospital. The St. Jude tumors were from a series reported previously[@R33] and processed into tissue microarrays. Sections were cut at 10 µm (UCSF) or 6 µm (St. Jude) and were incubated in 0.01 M citrate buffer (pH 6.0) at 95°C for 30 minutes for antigen retrieval before immunostaining. The analysis to detect primary cilia was done blind as to the diagnosis or gene expression signature of the tumor. We used antibody to acetylated tubulin to detect primary cilia and antibody to γ-tubulin or pericentrin to detect the basal body.

Statistical analysis {#S9}
--------------------

We used Student's *t*-test to compare BrdU^+^ cells in the embryonic EGL, Log-rank test to compare survival curves, Pair Wise Fixed Relocation Randomization test in Relative Expression Software Tool (REST©) to compare qRT-PCR results[@R40], and Chi-square test to test the association of medulloblastoma subgroups and presence/absence of primary cilia.
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![Kif3a is required for SmoM2-driven medulloblastoma formation\
(**a**) Hematoxylin stained sagittal sections of control and mutant cerebella. Expression of SmoM2 in GNPs using *hGFAP::Cre* induces medulloblastoma by P10. Removal of *Kif3a*, an essential gene for ciliogenesis, in SmoM2 expressing cells completely blocks tumorigenesis resulting in atrophic cerebella similar to those of *hGFAP::Cre*;*Kif3a^fl/fl^* mice. (**b**) SmoM2-YFP is highly enriched in primary cilia (green, arrow) associated with the basal body (anti-γ-tubulin staining, shown in red, arrowhead). In *hGFAP::Cre*; *SmoM2^fl/+^*; *Kif3a^fl/fl^* mice only the basal body is present (arrowhead). (**c, d**) BrdU incorporation (1h survival) at E16. GNPs proliferation in *hGFAP::Cre*; *SmoM2^fl/+^*; *Kif3a^fl/fl^* is similar to that observed in *hGFAP::Cre*; *Kif3a^fl/fl^* or wild type mice[@R8]. In contrast, already by E16, *hGFAP::Cre*; *SmoM2^fl/+^* mice show an expanded EGL containing significantly more proliferating cells. \*: *P* \< 0.05. Scale bar = 0.5 mm (**a**), 5 µm (**b**) and 100 µm (**c**).](nihms136737f1){#F1}

![Kif3a suppresses Gli2ΔN-driven medulloblastoma formation\
(**a--c**) Hematoxylin and eosin (H&E) stained sagittal sections of control and mutant cerebella at P23. (**a**) *hGFAP::Cre*; *CLEG2^fl/+^* mice have ectopic clusters of cells (arrows) without tumor formation. (**b**) All *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice develop medulloblastomas between P11 and P30. A green dotted line in **b** demarcates domains of the tumors containing type 1 and type 2 tumor cells (see text). (**c**) High magnification of red box in **b**, showing the two domains with different cell types. (**d**) Western blot analysis of Gli3 proteins isolated from P23 cerebella shows the decrease of Gli3 repressor (Gli3R) in *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice compared with wild-type and *hGFAP::Cre*; *CLEG2^fl/+^* mice. Asterisk indicates a nonspecific band, which serves as a loading control. This banding pattern is similar to a previous report, which showed that this Gli3 antibody detects specific Gli3 bands that are absent in Gli3 mutants and non-specific bands[@R38]. (**e,f**) BrdU-labeling (1h survival) reveals that the ectopic clusters in *hGFAP::Cre*; *CLEG2^fl/+^* mice are not proliferating (arrows), while tumors in *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice contained many proliferating cells. (**g**) *hGFAP::Cre*; *CLEG2^fl/+^*; *Kif3a^fl/fl^* mice (*P* \< 0.001) and *hGFAP::Cre*; *CLEG2^fl/+^*; *Gli3^Xt/+^* mice (*P* \< 0.02) die significantly earlier than *hGFAP::Cre*; *CLEG2^fl/+^* mice. (**h**) Hh-responsive genes are up-regulated in both SmoM2- and Gli2ΔN-driven tumors (see text). \*: *P* \< 0.05. Scale bar = 0.5 mm (**a,b,e,f**), 10 µm (**c**).](nihms136737f2){#F2}

![Primary cilia are present in a subset of human medulloblastomas\
(**a**) Nine of twenty-three classic and five of six desmoplastic medulloblastomas have primary cilia in most cells. Eight of nine anaplastic medulloblastomas have few or no ciliated cells (shown is an example of non-ciliated anaplastic medulloblastoma). Cilia and basal bodies are stained by anti-acetylated tubulin (green, arrows) and anti-γ-tubulin (red, arrowheads), respectively. Scale bar = 5 µm. (**b**) Model summarizing results of dual roles of primary cilia in SmoM2- and Gli2ΔN-driven tumorigenesis. SmoM2 is insensitive to inhibition by Ptch1 and constitutively localizes to the cilia, where it activates Gli2 and inhibits Gli3 repressor (Gli3R) formation, leading to medulloblastoma (top left). Without the cilia, SmoM2 cannot activate downstream pathways; cerebellum remains small as in ciliary mutants[@R8] and no tumors develop (bottom left). Gli2ΔN is constitutively active and independent of primary cilia, yet these mice do not develop medulloblastoma possibly due to thepresence of Gli3 repressor; however, these mice develop type 2 tumors later in life (top right). In the absence of cilia, Gli2ΔN induces medulloblastoma and type 2 tumors earlier in life. This may be due to the elimination of Gli3 repressor when cilia are removed (bottom right).](nihms136737f3){#F3}

###### 

Primary cilia are present almost exclusively in medulloblastomas with either HH or WNT signaling activation.

  --
  --

Samples that were hard to be determined for the presence of cilia due to suboptimal staining are labeled as equiv.
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